234 related articles for article (PubMed ID: 23109455)
21. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment.
Arnon R; Calderon JF; Schilsky M; Emre S; Shneider BL
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):596-602. PubMed ID: 17460493
[TBL] [Abstract][Full Text] [Related]
22. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.
Lowette KF; Desmet K; Witters P; Laleman W; Verslype C; Nevens F; Fevery J; Cassiman DM
Eur J Gastroenterol Hepatol; 2010 May; 22(5):564-71. PubMed ID: 20042865
[TBL] [Abstract][Full Text] [Related]
23. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients.
Dzieżyc K; Karliński M; Litwin T; Członkowska A
Eur J Neurol; 2014 Feb; 21(2):332-7. PubMed ID: 24313946
[TBL] [Abstract][Full Text] [Related]
24. Role of Oxidative Stress in the Worsening of Neurologic Wilson Disease Following Chelating Therapy.
Kalita J; Kumar V; Ranjan A; Misra UK
Neuromolecular Med; 2015 Dec; 17(4):364-72. PubMed ID: 26224517
[TBL] [Abstract][Full Text] [Related]
25. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease.
Lozano Herrero J; Muñoz Bertrán E; Ortega González I; Gómez Espín R; López Espín MI
Gastroenterol Hepatol; 2012 Dec; 35(10):704-7. PubMed ID: 22609346
[TBL] [Abstract][Full Text] [Related]
26. Early Onset of Wilson Disease: Diagnostic Challenges.
Wiernicka A; Dądalski M; Jańczyk W; Kamińska D; Naorniakowska M; Hüsing-Kabar A; Schmidt H; Socha P
J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):555-560. PubMed ID: 28753182
[TBL] [Abstract][Full Text] [Related]
27. Neurological worsening in Wilson disease - clinical classification and outcome.
Mohr I; Pfeiffenberger J; Eker E; Merle U; Poujois A; Ala A; Weiss KH
J Hepatol; 2023 Aug; 79(2):321-328. PubMed ID: 37116715
[TBL] [Abstract][Full Text] [Related]
28. Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease.
Zhang J; Xiao L; Yang W
BMC Neurol; 2020 Jun; 20(1):255. PubMed ID: 32593295
[TBL] [Abstract][Full Text] [Related]
29. Wilson disease: histopathological correlations with treatment on follow-up liver biopsies.
Cope-Yokoyama S; Finegold MJ; Sturniolo GC; Kim K; Mescoli C; Rugge M; Medici V
World J Gastroenterol; 2010 Mar; 16(12):1487-94. PubMed ID: 20333789
[TBL] [Abstract][Full Text] [Related]
30. Zinc treatment for symptomatic Wilson disease: moving forward by looking back.
Schilsky M
Hepatology; 2009 Nov; 50(5):1341-3. PubMed ID: 19877301
[No Abstract] [Full Text] [Related]
31. Worsening of Wilson disease following penicillamine therapy.
Kalita J; Kumar V; Chandra S; Kumar B; Misra UK
Eur Neurol; 2014; 71(3-4):126-31. PubMed ID: 24356057
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of Wilson's disease with penicillamine and zinc salts: a follow-up study].
Li M; Zhang YH; Qin J
Zhonghua Er Ke Za Zhi; 2003 Feb; 41(2):119-22. PubMed ID: 14759316
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and management of Wilson's disease: results of a single center experience.
Medici V; Trevisan CP; D'Incà R; Barollo M; Zancan L; Fagiuoli S; Martines D; Irato P; Sturniolo GC
J Clin Gastroenterol; 2006; 40(10):936-41. PubMed ID: 17063115
[TBL] [Abstract][Full Text] [Related]
34. Wilson disease in 71 patients followed for over two decades in a tertiary center in Saudi Arabia: a retrospective review.
Al Fadda M; Al Quaiz M; Al Ashgar H; Al Kahtani K; Helmy A; Al Benmousa A; Abdulla M; Peedikayil M
Ann Saudi Med; 2012; 32(6):623-9. PubMed ID: 23396027
[TBL] [Abstract][Full Text] [Related]
35. Significant heterogeneity in the diagnosis and long-term management of Wilson disease: Results from a large multicenter Spanish study.
Berenguer M; Vergara M; Almohalla C; Hernandez A; Blanco S; Testillano M; Girona E; Casado M; García M; Catalina MV; Muñoz C; Gutierrez ML; Molina E; Romero M; Otero A; Hernáez-Alsina T; Bernal-Monterde V; Lorente S; Masnou H; Bonet L; Soto S; Gisbert C; Valer MP; Gomez J; Pacheco G; Morillas J; Gonzalez M; Dominguez N; Lazaro M; Pascual S; Castelló I; Gonzalez R;
Gastroenterol Hepatol; 2023 Oct; 46(8):577-584. PubMed ID: 36372257
[TBL] [Abstract][Full Text] [Related]
36. Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson's disease.
Dzieżyc K; Litwin T; Chabik G; Członkowska A
Funct Neurol; 2015; 30(4):264-8. PubMed ID: 26727705
[TBL] [Abstract][Full Text] [Related]
37. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.
Merle U; Schaefer M; Ferenci P; Stremmel W
Gut; 2007 Jan; 56(1):115-20. PubMed ID: 16709660
[TBL] [Abstract][Full Text] [Related]
38. Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease.
Kazemi K; Geramizadeh B; Nikeghbalian S; Salahi H; Bahador A; Reza Nejatollahi SM; Dehghani SM; Dehghani M; Kakaei F; Malek-Hosseini SA
Exp Clin Transplant; 2008 Dec; 6(4):261-3. PubMed ID: 19338486
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis and treatment of Wilson's disease.
Subramanian I; Vanek ZF; Bronstein JM
Curr Neurol Neurosci Rep; 2002 Jul; 2(4):317-23. PubMed ID: 12044251
[TBL] [Abstract][Full Text] [Related]
40. Observation on the changes of clinical symptoms, blood and brain copper deposition in Wilson disease patients treated with dimercaptosuccinic acid for 2 years.
Zhou XX; Pu XY; Xiao X; Chen DB; Wu C; Li XH; Liang XL
J Clin Neurosci; 2020 Nov; 81():448-454. PubMed ID: 33222961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
